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ABSTRACT

MUTATIONAL STUDIES IN THE dNTP BINDING POCKET OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE

by
Smita Shukla

It was earlier postulated that Gln 91 of HIV-1 RT stabilizes the side chain of Tyr 183 via
hydrogen bonding interaction between 0(H) of Y183 and CO of Q91 (Harris et al.,
BIOCHEMISTRY 37: 9630, 1998). In an attempt to understand the function of Gln 91 in
the catalytic mechanism, mutants of this residue (Gln91--->Ala and Gln91-->Asn) were
generated and subjected to an in-depth analysis. The efficiency of reverse transcription of
natural U5-PBS HIV-1 RNA template was severely impaired by both conservative and
non-conservative substitutions from Gln--->Asn and Gln--->Ala, a result similar to that
observed with Y-->F substitution at position 183. The major defect seems to be at the
substrate binding step as the processivity of these mutants was not affected while the
extent of primer utilization correlated with the loss of their polymerase activity.
Curiously, these mutant derivatives of Q91 were found to be highly resistant to ddNTPs
and exhibited greater stringency in discriminating between correct and incorrect
nucleotides. These results suggest possible interaction of Q91 with other residues in the
dNTP binding pocket that may be responsible for conferring greater flexibility to the
pocket. A model is proposed which suggests that subtle structural changes due to
mutation in the region may have influenced the active site of the enzyme that may
interfere in the substrate recognition.
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CHAPTER 1
INTRODUCTION

This thesis pertains to investigations on structure and function of reverse transcriptase
(RT) of human immunodeficiency virus (HIV), the retrovirus known to be the causative
agent of acquired immune deficiency syndrome, viz. AIDS. This clinical syndrome,
characterized by a marked reduction in the number of CD4+ cells along with the
development of opportunistic infections (sometimes leading to cancer e.g. Kaposi's
Sarcoma), results from persistent replication and spread of HIV (Levy, 1998). In the life
cycle of HIV in human cells, RT plays a critical role in the synthesis of double-stranded
pro-viral DNA, which then gets integrated into the host human cell DNA (Coffin, 1999).
Ever since the discovery of HIV in 1983, science has responded to the challenge
of AIDS by rapidly identifying etiology, describing pathogenesis and transmission
routes, and developing diagnostic tests and treatment. However, this did not prevent the
global spread of HIV, with over 25 million fatal cases so far, another 33 million
infected, and disastrous socioeconomic and demographic consequences. To meet the
goal of universal access to prevention, treatment and care by 2010 would require a
quadrupling of funding to an estimated US$42 billion by 2010, including adequate
overall strengthening of healthcare systems (Kallings, 2008).

1

2
1.1 Structure of the Virion
1.1.1 Visualization of HIV Structure
The morphology and overall arrangement of HIV particles have been characterized by a
host of electron microscopic observations (in thin sections), However, the visualization of
mature and immature HIV virions by cryo-electron microscopy (which maintains the
sample in a thin layer of vitrified water) has been successful to some extent (Coffin,
1992; Vogt, 1997). HIV particles appear to be roughly spherical, membrane-bound
structures, with diameter between 1000-3000A ° . These include budding membranebound virus-like particles (immature virions) and mature particles. The panoply of
shapes and sizes of particles in a preparation (for electron microscopic examination)
demonstrates that particle formation does not require the isomeric structure and that the
assembling of HIV particles is an enormously robust process. As Wilk and Fuller (1999)
stated in their excellent review, "The virus appears to be less concerned about the
icosahedral symmetry than the structural biologist." Notwithstanding this apparent
setback in the structural studies of HIV, recent findings have expanded our knowledge of
its major structural proteins. Further challenge lies in understanding the changes in
structure and the interactions of these components during assembly and maturation.
1.1.2 Overall Structural Features of HIV (McClure et al., 1988; Levy, 1998)
HIV is a member of the Lentivirus genus, which includes retroviruses having complex
genomes and cone-shaped capsid core particles. The general features of the mature HIV
virion and known or postulated localization of mature proteins are schematically depicted
in Fig.1.1 (McClure et al., 1988). All lentiviruses are enveloped by a lipid bilayer which
seems to be derived from the host cell membrane. Exposed surface glycoproteins (SU;
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gp120) are anchored to the VIrIOn VIa interactions with the transmembrane
protein (TM; gp41). The lipid layer also contains quite a few host cell membrane
proteins, such as: major histocompatibility antigens, actin, and ubiquitin. A matrix shell
possessing about 2000 copies of the matrix protein (MA; p 17) lines the inner surface of
the viral membrane.

Lipid
Integrase
RT

Protease
p6
p7NC

RNA
gp41
gp120

p24,CA
p17,MA

I

/

Figure 1.1 Structure of HIV -1 Virion Particle.
I

At the center of the virion, a core particle compose\! of some 2000 copies of the
I

Capsid protein (CA; p24) is localized. This capsid particle also clusters two copies of the
viral RNA genome, which are stabilized as a ribonucleoprotein complex with
approximately 2000 copies of the nucleocapsid protein (NC; p7). The core particle also
\

\

houses three essential virally encoded enzymes: Protease (PR), reverse transcriptase (RT)
\
I:

~

#

..

and integrase (IN). The virion encloses the accessory proteins: Nef, Vif and Vpr. Three
additional virally encoded accessory proteins viz., Rev, Tat and Vpu, which provide
essential regulatory functions in the host cell, do not appear to be packaged in the virion.
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1.2 HIV Replication Cycle
Mature HIV-1 particles begin their life-cycle by recognition of the target cells, viz., the
cells bearing CD4+, a protein that normally functions in immune recognition. The early
phase of the life cycle begins with CD4+ recognition and proceeds step-wise to the
formation, and later, to the integration of the pro-viral DNA into the host cellular DNA.
The late phase comprises the events from the transcription of the integrated pro-viral
genome to the virus budding and maturation.
1.2.1 Entry to the Cell
HIV enters macrophages and CD4 + T cells by the adsorption of glycoproteins on its
surface to receptors on the target cell followed by fusion of the viral envelope with the
cell membrane and the release of the HIV capsid into the cell (Chan et al., 1998; Wyatt et
al., 1998). Entry to the cell begins through interaction of the trimeric envelope complex
(gp160 spike) and both CD4 and a chemokine receptor (generally either CCR5 or
CXCR4, but others are known to interact) on the cell surface (Chan et al., 1998; Wyatt et
al., 1998). gp120 binds to integrin a4137 activating LFA-1 the central integrin involved in
the establishment of virological synapses, which facilitate efficient cell-to-cell spreading
of HIV-1 (Arthos et al., 2008) The gp160 spike contains binding domains for both CD4
and chemokine receptors (Chan et al., 1998; Wyatt et al., 1998). The first step in fusion
involves the high-affinity attachment of the CD4 binding domains of gp120 to CD4. Once
gp120 is bound with the CD4 protein, the envelope complex undergoes a structural
change, exposing the chemokine binding domains of gp120 and allowing them to interact
with the target chemokine receptor (Chan et al., 1998; Wyatt et al., 1998). This allows for
a more stable two-pronged attachment, which allows the N-terminal fusion peptide gp41
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to penetrate the cell membrane (Chan et al., 1998; Wyatt et al., 1998). Repeat
sequences in gp41, HR1 and HR2 then interact, causing the collapse of the extracellular
portion of gp41 into a hairpin. This loop structure brings the virus and cell membranes
close together, allowing fusion of the membranes and subsequent entry of the viral capsid
(Chan et al., 1998; Wyatt et al., 1998).

Figure 1.2 The HIV Replication Cycle.
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Once HIV has bound to the target cell, the HIV RNA and various
enzymes, including reverse transcriptase, integrase, ribonuclease and protease, are
injected into the cell (Chan et al., 1998). During the microtubule based transport to the
nucleus, the viral single strand RNA genome is transcribed into double strand DNA,
which is then integrated into a host chromosome.
1.2.2 Replication and Transcription
Once the viral capsid enters the cell, an enzyme called reverse transcriptase liberates the
single-stranded (+)RNA from the attached viral proteins and copies it into a
complementary DNA (Zheng et al., 2005). This process of reverse transcription is
extremely error-prone and it is during this step that mutations may occur. Such mutations
may cause drug resistance. The reverse transcriptase then makes a complementary DNA
strand to form a double-stranded viral DNA intermediate (vDNA). This vDNA is then
transported into the cell nucleus. The integration of the viral DNA into the host cell's
genome is carried out by another viral enzyme called integrase (Zheng et al., 2005)
This integrated viral DNA may then lie dormant, in the latent stage of HIV
infection (Zheng et al., 2005). To actively produce the virus, certain cellular transcription
factors need to be present, the most important of which is NF-κB (NF kappa B), which is
upregulated when T cells become activated (Hiscott et al. 2001). This means that those
cells most likely to be killed by HIV are those currently fighting infection.
In this replication process, the integrated provirus is copied to mRNA which is
then spliced into smaller pieces. These small pieces produce the regulatory proteins Tat
(which encourages new virus production) and Rev. As Rev accumulates it gradually
starts to inhibit mRNA splicing (Pollard et al., 1998). At this stage, the structural proteins
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Gag and Env are produced from the full-length mRNA. The full-length RNA is
actually the virus genome; it binds to the Gag protein and is packaged into new virus
particles.
HIV-1 and HIV-2 appear to package their RNA differently; HIV-1 will bind to
any appropriate RNA whereas HIV-2 will preferentially bind to the mRNA which was
used to create the Gag protein itself. This may mean that HIV-1 is better able to mutate
(HIV-1 infection progresses to AIDS faster than HIV-2 infection and is responsible for
the majority of global infections).
1.2.3 Assembly and Release
The final step of the viral cycle, assembly of new HIV-1 virons, begins at the plasma
membrane of the host cell. The Env polyprotein (gp160) goes through the endoplasmic
reticulum and is transported to the Golgi complex where it is cleaved by protease and
processed into the two HIV envelope glycoproteins gp41 and gp120. These are
transported to the plasma membrane of the host cell where gp41 anchors the gp120 to the
membrane of the infected cell. The Gag (p55) and Gag-Pol (p160) polyproteins also
associate with the inner surface of the plasma membrane along with the HIV genomic
RNA as the forming virion begins to bud from the host cell. Maturation either occurs in
the forming bud or in the immature virion after it buds from the host cell. During
maturation, HIV proteases cleave the polyproteins into individual functional HIV
proteins and enzymes. The various structural components then assemble to produce a
mature HIV virion (Gelderblom, 1997). This cleavage step can be inhibited by protease
inhibitors. The mature virus is then able to infect another cell.
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1.3 Reverse Transcriptase
In retroviruses such as the human immunodeficiency virus type 1 (HIV-1), reverse
transcriptase (RT) is the sole enzyme necessary for the catalytic transformation of singlestranded viral RNA into the double-stranded linear DNA that is integrated into host cell
chromosomes. HIV-1 RT is composed of two subunits of 66 kDa and 51 kDa (p66 and
p51). The N-terminal 440 amino acids of p66 constitute the polymerase domain and the
C-terminal 120 amino acids comprise the RNase H domain. The p51 subunit of HIV-1 RT
corresponds to the polymerase domain of the p66 subunit (Jacobo Molina., 1993). The
polymerase domain of the p66 subunit is folded into an open conformation containing the
polymerase active site cleft while the inert p51 subunit is closed and compact (Wang et
al., 1994). The polymerase cleft resembles open right hand and folds into fingers, palm
and thumb sub-domains.

1.4 Drugs Targeting RT
Considerable effort has been expended in discovering compounds that inhibit HIV-1 RT,
an essential viral enzyme which is responsible for the conversion of the (+) singlestranded RNA viral genome into double-stranded DNA (dsDNA), which subsequently
becomes integrated into host cell chromosomes. RT is an attractive target of drug
therapy not only because it is essential for HIV replication, but also it is not required for
normal host cell metabolism.
HIV-1 RT inhibitors can be divided into two classes (Larder, 1993): nucleoside
analogs (also referred to as nucleoside inhibitors, chain terminators, or competitive
inhibitors) and non-nucleoside inhibitors (also refereed to as TIBO-like inhibitors). Many
of the nucleoside analogs (Balzarini et al., 1999) cause termination of the growing DNA
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chain. Because they closely resemble normal nucleosides, nucleoside analog
inhibitors can be added to the newly synthesized DNA during reverse transcription.
Elongation is blocked because the chain terminators lack the 3'-OH functional group
essential for incorporation of additional nucleotide. All of the currently marketed AIDS
drugs are of this class. Although these drugs are selective for HIV-1RT, they are not
highly specific and can inhibit normal cellular polymerases, causing serious side effects.
The non-nucleoside inhibitors do not function as chain terminators, and do not
bind at the dNTP-binding site. These compounds are non-competitive inhibitors with
respect to dNTP. Several families of such compounds have been reported, including
TIBO (Pauwels et al., 1990), dipyridodiazepinone, pyridinone, BHAP, HEPT, α-APA
and inophyllum derivatives (reviewed, Tantillo et al., 1994). Although these inhibitors
exhibit striking structural differences and fall into several chemical groups, they all
contain aromatic moieties and bind to the same hydrophobic pocket in HIV-1RT.

1.5 Drug Resistance
Although there has been substantial progress in blocking HIV-1 replication in vitro, the
success of most in vitro experiments and numerous clinical trials to date has been limited
due to the emergence of viral strains that have point mutations in the region encoding
HIV-1RT and prevent these drugs from inhibiting RT. Mutations that render HIV-1RT
drug-resistant have been encountered with every RT inhibitor so far tested. Sequence
analysis has identified the point mutations responsible for resistance but a great deal still
remains to be known concerning the molecular basis of resistance mechanisms. The
structure determination of HIV-1RT with bound template-primer reported by Jacobo-
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Molina et.al., in 1993 (Jacobo-Molina et al., 1993), provides the location of
HIV-1RT inhibitor-resistance mutations in a three-dimensional context, which makes it
possible to formulate hypotheses for the mechanisms of drug resistance that are based on
the structure and the location of the specific mutations that lead to drug resistance.

1.6 Background of this Project
The rapid emergence of Human Immunodeficiency Virus (HIV-1) strains resistant to
specific inhibitors has frustrated all efforts to control the spread of acquired
immunodeficiency syndrome. Dynamics of HIV-1 replication in vivo have demonstrated
that within 2-4 weeks of treatment with nucleoside analogs, the wild type virus in plasma
is completely replaced by the drug resistant mutants (Wei et al., 1995; Ho et al., 1995).
The single stranded HIV-1 viral RNA genome is efficiently converted into the
double stranded proviral DNA by the virally encoded reverse transcriptase, which is
essential for viral replication and establishing infection. The functional form of mature

HIV 1 RT contains two subunits, p66 and p51; the smaller subunit is derived from the
-

proteolytic cleavage of the larger subunit (di Marzo-Veronese et al., 1986; Lightfoote et
al., 1996 ). A number of high resolution crystal structure of HIV-1 RT in apocrystal
form, liganded with inhibitors, bound with DNA as well as the most elegantly solved
structure of enzyme-DNA-dNTP ternary complex are now available. In the crystal
structure, the polymerase domain of the larger subunit is folded into an open
conformation containing the polymerase active site cleft while the inert smaller subunit is
closed and compact (Wang et al., 1994). The polymerase cleft resembles open right hand
and folds into fingers, palm and thumb sub-domains. A large number of amino acid
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residues in the polymerase domain of this enzyme have been subjected to
extensive mutagenesis. However, only a few of them have been subjected to in-depth
biochemical characterization in order to understand their functional role in the catalysis.
The mutant derivatives of amino acid residues at positions 65, 72, 89, 110, 115, 151, 160,
183, 184, 185, 186, 219, 249, 307, 311 and most of the residues in Motif- E (residues
227-237) and in the thumb sub domain (residues 253-271) have been extensively
characterized and their functional roles in the context of three-D structure have been
proposed.
Earlier the mutant derivatives of catalytically important residues of YMDD motif
have been extensively analyzed and their functional roles in the 3-D context have been
proposed. One of the residues in this motif that has been studied in detail is tyrosine at
position 183 (Harris et al., 1998). A conservative substitution of Tyrl 83 to Phe183
resulted in 70% loss of polymerase activity with a significant increase in the fidelity of
DNA synthesis. Based on experimental results and molecular modeling studies, it was
predicted that the side chain of Y 183 is stabilized via hydrogen bonding interaction with
the side chain of Gln 91 (Harris et al., 1998). This interaction was indeed observed in a
recently solved 3-D crystal structure of RT-DNA-dNTP ternary complex (Huang et al.,
1998). The loss of polymerase activity by Tyr ---> Phe substitution may have manifested
due to loss of this hydrogen bonding interaction. Thus, similar influence on the
polymerase function of the enzyme may be expected if this hydrogen bonding interaction
is perturbed by mutation at position 91. This work reports here that the removal or
reduction in the length of the side chain at position 91 (Gln ---> Ala or Gln —+ Asn)
resulted in significant loss of polymerase activity of the enzyme probably due to loss of
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hydrogen bonding interaction with Tyr183. These results have been discussed
in the context of the recently solved three dimensional crystal structure of HIV-1 RTDNA-dNTP ternary complex (Huang et al., 1998).

CHAPTER 2
MATERIALS AND METHODS

Mutagen-M13 in vitro mutagenesis kit was obtained from Bio-Rad laboratories while
Sequenase and DNA sequencing reagents were from U.S. Biochemicals. Restriction
endonucleases, DNA-modifying enzymes and HPLC-purified dNTPs were from
Boehringer Mannheim or Promega; IDA-Sepharose for immobilized metal affinity
chromatography (IMAC) was purchased from Pharmacia and 32P-labeled dNTPs and
ATP were obtained from DuPont / New England Nuclear Corp. Synthetic templateprimers, sequencing primers and mutagenic oligonucleotides were synthesized at the
Molecular Resource Facility at UMDNJ. An HIV-1 RNA expression clone pHIV-PBS
was a generous gift from Dr. M.A. Wainberg (Lee et al., 1998). All other reagents were
of the highest available purity grade and were purchased from Fisher, Millipore Corp.,
Boehringer Mannheim, and Bio-Rad.

2.1 Expression of Plasmid Clones and In Vitro Mutagenesis
Two recombinant plasmids, pKK-RT66 and pET-28a-RT51 containing P66 and P51
encoding regions were used for isolating wild type heterodimeric HIV-1 RT (Pandey et
al., 1996). The smaller subunit contained His-tag sequences at the N-terminal region.
The EcoR I and Kpn1 fragment (1.432 kb) of pKK-RT66 encoding the polymerase
domain of HIV-1 RT was sub cloned in bacteriophage M13 mp18 and used as the
template for site directed mutagenesis. The mutagenesis protocol-using dU containing
DNA template was essentially as described by Kunkel et al, 1987. After ascertaining the

13
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mutation in M13 by DNA sequencing, the desired mutation was introduced in both the
subunits as follows: The EcoRI and Kpn1 fragment from M13 mpl 8 was cloned in
RT66 expression cassette and the Ball and Kpn I fragment was cloned in RT51
expression cassette.

2.2 Polymerase Activity Assay
An HIV-RNA expression clone (pHIV-PBS) was used for the preparation of U5-PBS
HIV-1 genomic RNA template as described earlier (Lee et al., 1998). Polymerase
activity of the WT and mutant enzymes was assayed on U5-PBS HIV-1 RNA and 49
mer U5-PBS DNA templates primed with 17-mer PBS primer. Assays were carried out
in a 50 uL volume containing 50 mM Tris HCl pH 8.0, 100 ug/mL bovine serum
albumin, 5 mM MgCl2, 1 mM dithiothreitol, 50 mM KCl, 100 nM TP, 100 uM dNTP
(25 µM of each of the four dNTPs) with one of them being 32 P labeled (luCi/assay
dCTP) and 50 ng/assay enzyme. Reactions were carried out at 37°C for 5 min and were
terminated by the addition of ice cold 5% trichloroacetic acid containing 5 mM
inorganic pyrophosphate. The samples were filtered on Whatman GF/B filters and
processed for radioactivity counting as described before (Lee et al., 1998).

2.3 Gel Analysis of Polymerase Reaction Products
32

For the gel analysis, 5'- P labeled 18 mer PBS DNA primer annealed with U5-PBS
HIV-1 RNA, 49 mer U5-PBS DNA template and homopolymeric Poly(rA).(dT)18
template primer was used in the polymerase reaction as described above. The primers
were end labeled with 32 P using T4 polynucleotide kinase and [y- 32 1] ATP (3,000 Ci /
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mmol) according to the standard protocol (Ausubel et al., 1987). The reaction mixture
contained 50 mM Tris HCl pH 8.0, 100 µg/mL bovine serum albumin, 5 mM MgCl2, 1
mM dithiothreitol, 50 mM KCI, 100 nM TP, 10µM of each of the four dNTPs with one of
them being 32P-labeled (0.2 µCi/nmol dNTP) and 50 ng enzyme in a total volume of 5
tit. The reactions were terminated by the addition of 5 pt of Sanger's gel loading dye
(Sanger et al., 1977) containing 20 mM EDTA. The extension products were resolved on
an 8% denaturing polyacrylamide (7M urea, lx TBE) sequencing gel.

2.4 ddNTP Sensitivity Assay
The template primers used in this assay included the 49 mer U5 PBS DNA template
primed with 32P -labeled 17- mer DNA primer. Samples were incubated at 25°C for 5
min prior to termination using equal volume of Sanger's dye as described before. Final
concentrations of dNTP and ddNTP used were 10 µM each. All other conditions were
similar to the polymerase assay.

2.5 rNTP Incorporation Assay
The ability of the wild-type and its mutant derivatives to incorporate rNTPs as substrate
was assayed on both RNA and DNA templates. The 115 PBS RNA and 49-mer US PBS
DNA primed with 32-P labeled 17-mer DNA were used as RNA-DNA and DNA-DNA
template primer. In each case, the reactions were initiated by the addition of the enzymes
in a reaction mixture containing dNTP (20µM final each) or rNTP (100µM final each).
The reactions were carried out in a total volume of 5 µL and terminated by the addition of
the loading dye as described before. The terminated reaction products were heated for 3
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minutes at 90 °C and resolved on an 8% denaturing polyacrylamide gel (7M urea, 1X
TBE) sequencing gel.

2.6 Processivity Assay
The processivity of the wild-type RT and its mutant derivatives was assayed using poly
(rA) template and 32P-labeled dT18 primer annealed together. The cold poly
(rA).(dT)18 was used as a trap at a final concentration of 0.5 µM of primer termini. In
reactions where processivity was assayed, enzymes were preincubated with the labeled
TP for 30 seconds and then synthesis was initiated by the addition of a solution
containing Mg-dNTP and trap. A control reaction was incubated for each enzyme for 5
min of synthesis time, which was not restricted by addition of trap and thus represented
maximum synthesis under the given experimental conditions. The efficiency of the trap
to bind any enzyme dissociated from the labeled TP was assessed in a reaction where the
RNA trap was added before the initiation of the reaction. The molar ratio of the labeled
TP to trap was approximately 1: 100 so the probability of an enzyme rebinding to
labeled TP was negligible. The final concentration of dNTP was 50µM and the reaction
was incubated for 5 minutes at 25°C before terminating it by addition of Sanger's dye
and resolving on the denaturing polyacryamide gel.

2.7 Extension of Primers in Presence of Three dNTPs
Labeled 17 mer primer annealed with a three fold excess of U5 PBS RNA was used for
determining the extent of misincorporation in the presence of only three dNTPs. The
labeled template primer was incubated with 10 ng WT or mutant enzymes at 25°C for 10
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min in a total volume of 5µL containing 50 mM Tris -HCL, pH 7.5, 1mM DTT, 0.1 mg
of BSA per ml, 5 mM MgC1 2 and only three dNTPs at a concenration of 200µM each. (A= dCTP, dGTP, dTTP; -C = dATP, dGTP, dTTP; -G= dATP, dCTP, dTTP; -T=
dATP, dCTP, dGTP) At the end of incubation the reaction was quenched by addition of
54 of Sanger's gel loading dye. The reaction products were analyzed on a denaturing 10
% polyacrylamide— 8M urea gel.

2.8 Measurement of Pyrophosphorolysis Reaction
Pyrophosphorolysis activity of the mutant enzymes was estimated by analyzing the
products of the reaction on denaturing polyacrylamide gels. The U5-PBS HIV-1 RNA
and 49-mer U5 PBS DNA templates primed with

³²P-labeled

17-mer PBS primer were

used for measurement of pyrophosphorolysis reaction. The 6µL reaction mixture
contained 50 µM Tris-HCL, pH 7.5, 1mM DTT, 100 µG BSA, 5mM MgCl2, 1mM
sodium pyrophosphate and 10ng enzyme/assay. The reactions were carried out for 60
minutes and quenched by addition of equal volume of Sanger's gel loading dye. The
samples were then heated at 95 °C and loaded on denaturing 12% polyacrylamide-8M
urea gel. The labeled products were detected by autoradiography.

CHAPTER 3
RESULTS

3.1 Construction and Purification of Mutant Enzymes
Two mutant derivatives of the residue at position 91 of HIV-1 RT were constructed and
expressed in Escherichia coli by the procedure described before(Pandey et al.,1996;
Harris et al., 1998). Two single substitutions were carried out. In the first one, the
functional side chain of Gln91 was abolished by replacement with Ala, and in the second
one, the replacement was by conservative Asn residue which displays similar geometry
and polarity in its side chain as that of Gln. The purified enzyme preparations were found
to be homogeneous with a purity of greater than 95%. The level of their expression,
solubility and yield as well as the chromatographic characteristics of all the mutant
proteins were identical with that of the wild type enzyme suggesting that the substitutions
at the mutation sites did not cause any perturbation in the enzyme structure. All the
mutants showed a heat inactivation pattern identical to the wild type enzyme (results not
shown), thus providing an additional evidence that these mutations had not altered the
folded structure of the enzyme protein.
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3.2 Polymerase Activity with RNA and DNA Templates

Figure 3.1 RNA and DNA—Directed DNA Polymerase Activity of WT HIV-1 RT and its Mutant
Derivatives. Three template -primers poly (rA).(dT) 18 , U5-PBS-RNA/18-mer DNA, and 49-mer
U5-PBS DNA/18-mer DNA primer were used to assess the extension reaction catalyzed by the
wild-type and mutant derivatives of HIV-1 RT. The primers labeled at the 5' end with 3² P were
annealed with the respective templates and used in the reactions carried out in a total volume of
61.11_, as described in Methods. Reactions quenched by the addition of Sanger's dye were analyzed
by 10% denaturing gel electrophoresis. Reactions carried out in presence of Mg²+ as divalent
cation are depicted in panel A and those carried out in presence of Mn ²+ as divalent cation are
depicted in panel B.

A number of mutations of HIV-1 RT have been shown to display differential
polymerase activity with different template primers. It has been earlier demonstrated that
alanine substitution at position 72 and 151 results in impairment in the polymerase
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activity by nearly an order of magnitude with RNA template while only a five-fold
reduction was seen with DNA directed reactions (Sarafianos et al., 1995; Kaushik et al.,
1997). In order to determine if the mutant derivatives of Gln91 also share the above
template effect, we evaluated their polymerase activities with different template primers.
Polymerase activities of the wild-type HIV-1 RT and its mutant derivatives were
assessed using poly (rA).(dT)18 as well as natural RNA and DNA templates
corresponding to the U5 PBS region of HIV-1 genome primed with a PBS primer. The
results depicted in Figure 3.1 indicate that both Q91A and Q91N mutant enzymes are
severely impaired in their polymerase activity in relation to the wild-type enzyme both
RNA and DNA templates. Q91A shows less activity compared with the Q91N mutant
enzyme. Interestingly, the extent of primer extension exhibited by Q91N mutant was
greatly reduced as compared to the wild type enzyme. Q91N mutant seems to pause more
frequently and accumulate shorter products although the degree of initial primer
utilization is similar to the wild type enzyme. In contrast, the extension product catalyzed
by Q91A is much longer than Q91N mutant despite lower initial utilization of the primer.
Notably, the observed 'pausing' pattern of Q91N mutant enzyme is valid on both RNA
and DNA templates. The overall pattern exhibited by the Q91N could be compared with
the Y183F mutant enzyme albeit with much lower activity (Harris et al., 1998).
Surprisingly, Q91N mutant was capable of exhibiting a significant increase in its
polymerase activity when Mg 2+ was replaced by Mn 2+ as divalent cation (Figure 3.1B).
In fact its polymerase activity seems to be a higher on homopolymeric template than the
wild type enzyme in presence of Mn 2+ . Mutant Q91A, however does not show any
substantial improvement in its polymerase activity. These observations hold true with
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respect to both homopolymeric or heteropolymeric RNA-DNA and DNA-DNA templateprimers. Thus, there seems to be a general improvement in the polymerase activity of
Q91N irrespective of the nature of the template used in presence of Mn ²+. Improvement
of polymerase activity on substitution of Mg ²+ with Mn ²+ has been reported in case of
other mutant RTs as well. This laboratory has earlier reported similar behavior of mutant
derivatives of Asp113, Y183 and Y115 which constitute the dNTP binding pocket of this
enzyme (Harris et al., 1998). Similar increase in polymerase activity has been reported by
Prasad, et al in their study of E89G mutant enzyme (Prasad et al., 1991).
These results suggest that Mn ²+ rather than Mg ²+ might help restore the effect of
Q91N mutation by coordinating with the surrounding residues better than for Q91A or
Y183F mutant enzyme. Thus, it is possible that the decreased polymerase activity of both
Q91A and Q91N may be due to subtle changes in the dNTP binding pocket. Such a
change in the pocket may also influence the fidelity, processivity of the enzyme as well
as its response to ddNTP inhibitors.
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3.3 Sensitivity to ddNTPs

Figure 3.2 Sensitivity of WT HIV-1 RT and its Mutant Enzymes to Dideoxy Nucleoside
Triphosphates. Effect of ddNTPs on the DNA synthesis catalyzed by the wild-type and mutant
enzymes was assessed on 49-mer U5-PBS DNA template primed with 5' 3² -P -labeled 17-mer PBS
primer. The final concentration of dNTP and ddNTP was 10[1.M each. Lane1 in each set
represents extension reaction in the absence of ddNTPs. Lanes 2 to 5 represent extension reaction
in presence of ddATP, ddCTP, ddGTP and ddTTP, respectively.

Dideoxynucleotides have been shown to be competitive inhibitors of HIV-1 RT
and have also been used for treatment of AIDS. The most potent single agent nucleoside
among the approved nucleoside inhibitors is (-)-2'3'-dideoxy-3'thiacytidine (3TC,
Lamivudine). However in both cell culture and infected patients, resistance to 3TC
develops rapidly. Resistant variants containing an M1841 alteration in RT gene appear
transiently and then are replaced by those with M184V alteration (Larder, 1995). This
M184V mutation has also been shown to confer a low level resistance to ddl and ddC
(Drosopoulas et al., 1993). An E89G substitution has been reported to confer multiple
resistance to ddNTPs in cell free analysis. In addition this mutation also confers
resistance to non-nucleoside RT inhibitors and foscarnet ( a Ppi analog ) both in-vivo and
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in-vitro (Prasad et al., 1991). It has been shown that substitution at 183 position confers
resistance to ddNTPs in-vitro (Harris et al., 1998). Since Y183 and Q91 have been
proposed to stabilize each other via hydrogen bonding interaction, it was interesting to
examine the influence of Q91 substitution on the ddNTP sensitivity of the mutant
enzymes as compared to the wild-type enzyme. As depicted in Figure 3.2, both mutations
vary in their ability to change response of RT to ddNTP analogs. The sensitivity of Q91A
mutant to ddNTP analogs does not significantly differ from the wild type enzyme. In case
of Q91N, comparison of lane representing synthesis in absence of ddNTP (lane 1) and in
the presence of ddATP, ddCTP, ddGTP and ddTTP (lanes 2-5), respectively, indicates
that Q91N substitution confers higher resistance to the ddNTP analogs. These results
suggest that the substitution has affected the enzyme activity in a manner similar to that
affected by E89G or Y183F alteration.
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3.4 Fidelity of the Wild-Type and Mutant Enzymes

Figure 3.3 Misinsertion and Mispair Extension Catalyzed by the Wild-Type Enzyme and its
Mutant Derivative in the Absence of a Single dNTP. Almost equivalent enzymes activities were
used in 6µL reactions carried out at 25 degree C for 15 min in presence of all four nucleotides
(lane 1), in absence of dATP (lane2), in absence of dCTP (lane 3), in absence of dGTP (lane 4)
and in absence of dTTP (lane 5). The extension reactions were analyzed by 10% denaturing
polyacrylamide gel electrophoresis as described in the Materials and Methods.

Several previous studies suggest that nucleoside analog resistance could be
associated with increased fidelity of HIV-1RT. Mutant enzymes such as M184V (Pandey
et al., 1996; Wainberg et al., 1996), E89G (Drosopoulas et al., 1996; Rubinek et al.,
1997), M184Leu (Bakhanashvili., et al., 1996) have been shown to exhibit higher enzyme
fidelity compared to the wild type enzyme. On the other hand, alterations such as Asn
67, Arg 70 have been shown to exhibit high levels of resistance to nucleoside analogs but
decreased enzyme fidelity (Anion et al., 1998; Canard et al., 1998). Hence, ddNTP
resistance and fidelity of the enzyme seem to be closely related to and affecting each
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other. Thus, it was interesting to examine if Q91A and Q91N mutations influenced these
functions of the enzyme. The assay employed here measures the net result of both
misinsertion and subsequent mispair extension by omitting a single dNTP from the
polymerization reaction.
Results depicted in Figure 3.3 suggest an overall increase in fidelity for both the
mutant enzymes compared to the wild type enzyme. Both the mutants are more
discriminatory for incorporation of dNTP as well as extension of primers once a
misinsertion has taken place as compared to the wild-type.
All these studies suggest a likelihood of both resistance to nucleoside analogs and
increase in fidelity might involve similar mechanism. That is the ability to incorporate or
reject an incoming dNTP or its analog is accompanied by the ability to recognize the
right dNTP for insertion. One might imagine that such high fidelity enzyme might be
advantageous for survival of the virus under the selection pressure of drug as it will be
less error-prone.
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3.5 Incorporation of rNTP versus dNTP

49 mer/17 mer

U5PBS RNA/17 mer

f

Figure 3.4 Utilization of rNTP in the Extension Reaction Catalyzed by the Wild-Type HIV-1 RT
and its Mutant Derivatives. The ability of the RT enzymes to catalyze incorporation of rNTP
substrates was examined using U5-PBS-RNA template and 49-mer U5-PBS DNA template each
annealed with 5' 3² P labeled 17-mer primer. d and r represent extension reactions carried out in
presence of 200µM dNTP and 500uM rNTP, respectively. All the reactions were carried out at 25
degree C for 20 min.

High discrimination of mutant enzymes exhibited with respect to incorporation of
ddNTP or incorrect dNTP prompted us to study the ability of the enzymes to discriminate
between rNTP and dNTP. To assay the ability of mutant enzymes to discriminate
between rNTP and dNTP, incorporation of both was studied on primed US-PBS RNA
and U5- PBS DNA templates as described. As is evident from Figure 3.4, none of the
mutant RT derivatives incorporate rNTPs as much as the wild-type RT. Both the mutant
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derivatives of RT seem to be more discriminatory as compared to the WT enzyme for
both DNA and RNA templates.

3.6 Pyrophosphorolysis

1 : (-) Sodium pyrophosphate
2 : (+) Sodium pyrophosphate

Figure 3.5 Pyrophosphorolysis Reaction Catalyzed by the Wild-Type Enzyme and its Mutant
Enzymes. The pyrophosphorolysis activity of the wild-type HIV-1 RT and its mutant derivatives
was detected by using heteropolymeric as described in the Materials and Methods. The
concentration of pyrophosphate and Mg +² in the reaction mixture was 1 mM and 5mM
respectively. The reaction products were analyzed on denaturing polyacrylamide-Urea gel as
described previously.
,

Pyrophosphorolysis is the reversal of polymerase activity resulting in cleavage of
the DNA primer from the 3' terminus in the presence of PPi and resulting in generation of
dNTPs as the products. Pyrophosphorolysis could be very important for survival of HIV
-1 under the pressure of drug therapy in vivo in order to remove the chain terminating 3'
deoxynucleotides thereby allowing additional chain elongation. Such enhanced
pyrophosphorolysis has been reported in HIV1 RT due to mutations D76N/K7OR in high
level resistance mutant D76N, K7OR, T215F, K219Q by Arion, et al. (1998). This
laboratory has previously reported that mutations in the residues from dNTP binding
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pocket change the pyrophosphorolysis activity of the enzyme in a template dependant
manner (Harris et al., 1998). It is possible the observed resistance to ddNTP for Q91A
and Q91N mutant enzymes could be due to the increased pyrophosphorolysis activity
which can generate 3'-OH by cleaving the ddNTP terminated primer. To examine this
possibility, pyrophosphorolysis activity of these mutant enzymes was studied. Both the
mutant derivatives displayed a significant amount of pyrophosphorolysis albeit lower
than the wild type enzyme (Figure 3.5). This indicates that reduced sensitivity to ddNTP
analogs displayed by these mutants is not due to the removal of terminal nucleotide from
the chain terminated primer during the synthesis. It has to be noted that both the mutant
derivatives are deficient in their polymerase activity. Anion, et al have reported a
concomitant increase in the processivity of the mutant enzyme D76N, K70R, T215F,
K219Q to compensate for the increased pyrophosphorolysis which is attributed to
alterations T215F and K219Q (Anion et al., 1998). Similarly, Canard et al. have proposed
that an RT enzyme containing AZT mutation is able to remove selectively an AZT-MP
terminated primer-template due to enhanced pyrophosphorolysis (Canard et al., 1998)
They further suggested that such a mutant has high affinity for the AZT-MP terminated
primer template thus increasing the likelihood of repair at this position. With such a
relationship between nucleoside analog resistance, pyrophosphorolysis and processivity it
was interesting to study processivity of the mutant derivatives under this study.
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3.7 Processivity of WT and its Mutant Derivatives

Figure 3.6 Processivity of HIV-1 RT and its Mutant Derivatives U5PBSRNA/17merDNA (TP).
(Processivity) - TP was first pre-incubated with RT proteins followed by the addition of trap. The
extension reaction was then initiated by adding a mixture containing dNTP and Mg++. (Trap
Control) - TP was first mixed with the trap mixture, followed by the addition of RT. The
extension reaction was then initiated by the addition of Mg++-dNTP mixture. This condition
blocked RT binding to the labeled TP. (No Trap) - TP was premixed with RT proteins and then
the extension reaction was initiated by the addition of Mg++- dNTP mixture. This condition
allowed multiple rounds of primer extension by RT proteins. All reactions were analyzed by 10%
denaturing gel electrophoresis.

Processivity of an enzyme is a measure of the number of nucleotides incorporated
into a primer strand during a single enzyme-template-primer binding eyent before the
enzyme dissociates from the template primer. Several mutations of HIV-1 RT have been
reported to affect processivity of the enzyme. Drug resistant RT containing the
substitution E89G and D76V have been shown to exhibit increased processivity (Kim et
al., 1999; Quan et al., 1998). It has been shown that the decreased processivity of Y183F
mutant RT could be restored by introduction of a second substitution of Met to Val at
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position 184 to the wild-type level (Harris et al., 1998). The processivity of Q91A and
Q91N on U5PBS RNA template annealed to 5' ³² P-labeled 17mer primer was examined
as described in the methods. The results as presented in Figure 3.6 indicate that under the
assay conditions, Q91N and Q91A appear equally processive. Also, they do not show
decrease in processivity compared to the wild-type enzyme.

CHAPTER 4
DISCUSSION

In the 3-D crystal structure of HIV-1 RT, Gln 91 is located on the B 5a - B 5b loop of
palm subdomain in the polymerase cleft (Kohlstaedt., 1993; Huang et al., 1998). In
previous studies from this laboratory, involvement of a residue at position 91 has been
suggested through its interaction with the side chain of Y183 - a constituent of highly
conserved YXDD motif found in all retroviral reverse transcriptases. Analysis of a 3-D
crystal structure based molecular model has indicated that the side chain of Q91 may
stabilize the side chain of Y183 through hydrogen bonding interaction (Harris et al.,
1998). This prediction was further supported by the mutant modeling in the present
studies using the available 3-D crystal structure of HIV-1 RT-DNA-dNTP ternary
complex where in one of the energetically favorable conformers, side chains of Y 183
and Q91 are positioned within distance appropriate for hydrogen bonding interaction.
The abolishment of this interaction by substitution of Tyr to Phe at position 183 resulted
in 70% loss of polymerase activity on both RNA and DNA templates with significant
increase in the fidelity (Harris et al., 1998). It was expected that loss of hydrogen
bonding interaction due to mutation at position 91 may also manifest enzyme
characteristic similar to Y183F mutant.
To elucidate the possible role of residue 91 in the HIV-1 RT, two mutations at
position 91 were introduced. Mutant enzymes Q91A carrying a non conservative
substitution and Q91N with a conservative substitution were studied. As predicted, both
substitutions affected the polymerase activity of the enzyme severely. Q91A mutant
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enzyme is more impaired in its polymerase activity than the Q91N mutant enzyme.
Interestingly, mutant enzyme Q91N shows polymerase activity comparable to the wild
type enzyme in the presence of Mn ²+ as divalent cation. Such results have been
previously described for mutations involving residues in the dNTP binding pocket (Harris
et al., 1998). These observations suggest that the decreased polymerase activity could be
due to the indirect effect of these mutations on the dNTP binding. This study of the
sensitivity of the mutant enzymes to the ddNTP analogs shows that both the enzymes are
more resistant to all the ddNTPs compared to the wild type enzyme. Enzyme fidelity as
studied by the polymerase reaction carried out in absence of one dNTPs suggest higher
fidelity of polymerase activity for both Q91N and Q91A mutants in relation to the wild
type enzyme. Interestingly, the results obtained for mutant Q91N clearly suggest that its
behavior is somewhat similar to both Y183F as well as E89G mutant derivatives of HIV1 RT( Harris et al., 1998; Prasad et al., 1991). These results also indicated that mutant
derivatives at position 91 exhibited marginal reduction in their ability to catalyze
pyrophosphorolysis activityof the enzyme. This laboratory has earlier reported
differential pyrophoshorolysis activity of RT mutants depending on the nature of the
template used (Harris et al., 1998). It was noted that Y183F mutant RT could exhibit
equivalent polymerase activities on DNA and RNA templates but was severely impaired
in its catalysis of pyrophosphorolysis on DNA template. Interestingly, both the mutants
(Q91N and Q91A) were found to be more resistant to ddNTPS than the wild type
enzyme. This suggested that any substitution at position 91 may offer greater stringency
to the enzyme in the selection of substrate. This may be due to partial loss of noncovalent interaction between the enzyme and the substrate as a result of both mutation
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and also modification of the substrate. This may result in reduced flexibility of the dNTP
binding pocket which may decrease the overall binding energy released from these weak
interactions. Although release of optimum binding energy is essential for lowering the
activation energy of the reaction, it also offers greater flexibility to the substrate binding
pocket. The increased resistance to ddNTP exhibited by both the mutants may be due to
reduced flexibility of their dNTP binding pocket. This contention was also supported by
the fact that both the mutant derivatives displayed higher fidelity as compared to the wild
type enzyme. However, between the two mutants, Q91N mutant derivatives of HIV 1 RT
is characterized by increased resistance to ddNTP analogs, and preferred usage of Mn ²+
instead of Mg ²+ as divalent cation for polymerase activity.
These characters are similar to the E89G mutant enzyme derivative that has been
isolated from HIV-1 infected cell culture ( Prasad., et al., 1991). However, E89G mutant
enzyme has been shown to posses higher processivity that probably compensates the
decreased forward synthesis due to decreased polymerase activity and increased fidelity
(Kim et al., 1999). An enzyme with increased pyrophosphorolysis compared to the
polymerase activity and decreased processivity could be detrimental to viral replication in
vivo. Increased fidelity tends to slow down the forward reaction further. We expect that
such a mutation may have difficulty surviving in vivo. Indeed, mutation at this position
has not so far been reported in HIV-1 variants isolated from AIDS patients or from HIV1 infected cell cultures. This supposition has been well supported by studies of
Tachedjian, et al (Tachedjian et al., 1996). While studying an inverse nature of
interaction between AZT resistant and PFA resistant mutants in vivo, they intended to
introduce PFA resistance notably, one involving residue 89 (E89K) into engineered AZT
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resistant background. Their attempts to recover infectious viruses containing mutation
Q91L were not successful and they concluded that the said mutation might not be viable.
Interestingly, the same authors could readily isolate E89K as a foscarnet
(phosphonoformic acid, PFA ), resistant mutation from MT-2 cells exposed to increasing
concentrations of the drug. This drug is a PPi analog used to treat infections due to
cytomegalo virus (such as retinitis ) in AIDS patients. The Antiretroviral effect of PFA
was one of the suggested explanations for improved survival of PFA treated patients in a
study that compared PFA with ganciclovir for treatment of CMV retinitis in AIDS
patients (Crumpacker, 1996; Oberg, 1989). Mutation E89G has been reported to be
resistant to PFA along with ddTTP, ddCTP, ddATP, ddGTP, AZTTP and 3TCTP. This
resistance and its increased processivity have been attributed to the interaction of Glu 89
with the penultimate nucleotide of the double stranded template (Drosopoulos et al.,
1996).
All these results point towards a possible involvement of residue 89 and 91 in the
pyrophosphorolysis activity of the HIV-1 RT probably via their interaction with the
template primer duplex. For any catalytically important residue for an enzyme activity, it
is expected to be fairly well conserved in sequences carrying out similar functions in
nature. Xiong and Eichenbush have studied the origin and evolution of retro-elements
based on their reverse transcriptase sequences ( Xiong., et al 1990). They have noted that
Q at position 91 has been conserved in 17 out of 29 retroviral sequences which is more
than 60 %. The same is very well conserved in the related viruses HIV-1, HIV-2 and SIV
(Korber et al., 1998). In the rest of the retroviral sequences reported, it is either serine (5
out of 29) or valine (6 out of 29). In case of Human Spuma retrovirus, it is asparagine.
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Interestingly, although the neighboring residues of 91 have been implicated in drug
resistance, there have been no reports on involvement of 91 in any functional aspects of
HIV 1 RT. Mutations such as Trp 88 Gly/Ser (Mellors et al., 1995), Glu89 Gly/Lys
(Prasad et al., 1991), Leu 92 Ile (Tachedjian et al., 1995) have all been implicated in the
resistance to foscarnet (PFA)- a pyrophosphate analogue used to treat AIDS patients.
Although these are located rather away from the putative pyrophosphate binding site,
their effect is probably exerted by an altered interaction of the mutant enzyme with the
template strand distorting the geometry of the polymerase active site and thereby
decreasing PPi binding. Absence of reports on involvement of residue 91 in drug
resistance might indirectly imply mutation at this position may not be viable. This
postulation is supported from the studies of Tachedjian, et al (Tachedjian et al., 1996)
where HIV-1 carrying Q91L mutation in the RT gene was found to be noninfectious and
replication incompetent. Additionally, results from our own laboratory suggest that
mutations at highly conserved neighboring positions 94 and 95 are extremely deleterious
to the polymerase activity of the HIV 1 RT.
In a 3-D crystal structure of the RT-DNA-dNTP ternary complex residue 89 is
positioned near the phosphate back bone of the second template nucleotide in the duplex
region, whereas residue at position 91 is within interacting distance from the side chain of
Gln 161 and sugar moiety of 3 rd template nucleotide in the duplex region. In order to
analyze the inter-atomic interactions, we carried out mutant modeling of Q91N in the
3D crystal structure of the ternary complex (Huang et al., 1998). We observed significant
variations in the side chain conformation of E89, in the mutant enzymes as compared to
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in the wild type enzyme. In the wild type enzyme, the side chain of K154 is in a position
to make salt bridge interactions with both phosphate group of template nucleotide and the
side chain of E89 while in the mutant enzymes (Q91N, Q91A), E89 is farther from K154
but closer to the phosphate group of 2 nd template nucleotide. This putative interaction
presents a very interesting scenario during the polymerase reaction. It is possible that in
the wild type enzyme, E89 is transiently interacting with K154 to destabilize its salt
bridge interaction with the phosphate group of template nucleotide and thus facilitating
the translocation of enzyme following each cycle of polymerization. In the mutant
enzymes, the salt bridge interaction between K154 and template nucleotide seems to be
more stable due to lack of interaction between E89 and K154 may cause enzyme
remaining in locked-in position resulting in strong pausing and subsequent translocation
following each polymerizing event. The reduction in the length of the side chain at
position 91 also results in the loss of hydrogen binding interaction with the side chain of
Y183. A significant change in the orientation of Q161 side chain was also noted. Q161
of ßE is located on conserved region very near to the dNTP and primer terminus but is
not solvent accessible in the RT-DNA binary complex (Jacobo Molina et al., 1993).
However, in the ternary complex, the side chain of Q161 may undergo conformational
change to influence the geometry of dNTP binding pocket. A conformational search of
Q91 and N91 side chain in the wild type and mutant model has shown a very interesting
pattern of interaction with Q161 and template strand. In case of wild type enzyme (that is
with Q at position 91) out of 21 allowed conformations, only six were within the
interacting distance from both Q161 (2.7 A —3.1A) and 3 rd template nucleotide (2.8 A-

3.1 A). In contrast, the conformational search of N91 yielded 9 allowed conformations
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all of which were within interacting distance from Q161 (2.7

A - 3.5 A) but farther from

the template strand. These observations suggest that stabilization of duplex region of
template-primer may be affected by Q to N substitution at position 91. The present
study as well as our previous observations (Harris et al., 1998) seems to suggest that Q91
and Q161 together with Y183 are also important constituents of the dNTP binding pocket
as judged by greater discriminatory property of Q91N and Y183F mutants against rNTP
and dNTP substrates.
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